< Back to previous page
Researcher
Kevin Hollevoet
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Oct 2013 → 30 Sep 2021
Projects
1 - 7 of 7
- Advancing DNA-based antibody therapeutics through evaluation and characterization of in vivo expression, complex antibody formats, and delivery formulationsFrom1 Sep 2020 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Intratumoral DNA-based immunomodulatory antibody therapy as a single or combined treatment with irradiation: A pre-clinical proof-of-concept studyFrom1 Oct 2019 → 30 Sep 2021Funding: BOF - projects
- Optimized muscle-specific expression and comprehensive characterization of antibody-encoding minicircles for the in vivo production of therapeutic antibodies in miceFrom1 Jan 2017 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
- Intratumoral gene transfer of immunomodulatory antibody combinations: a preclinical proof-of-concept studyFrom1 Oct 2016 → 19 Nov 2021Funding: FWO fellowships
- Non-viral gene transfer for in vivo production of therapeutic antibodies: Antibody characterization, vector biosafety and anti-HER2 antibody combination therapyFrom1 Oct 2015 → 30 Sep 2017Funding: IOF - Industrial Research Fund
- DNA minicircles for in vivo expression of anti-HER2 trastuzumab: Optimizing electroporation-based delivery and establishing anti-tumor activity in a mouse breast cancer modelFrom1 Jan 2015 → 31 Dec 2017Funding: FWO research grant KAN
- Non-viral gene transfer for the in vivo expression of therapeutic antibodies: a proof-of-concept study in cancer.From1 Oct 2013 → 1 Jun 2016Funding: FWO fellowships
Publications
1 - 10 of 22
- Intratumoral gene transfer of immunomodulatory antibody combinations: a preclinical proof-of-concept study(2021)
Authors: Liesl Jacobs, Paul Declerck, Adrian Liston, Kevin Hollevoet
- UNLOCKING THE POTENTIAL OF PLASMID-BASED ANTIBODY GENE TRANSFER(2021)
Authors: Giles Vermeire, Paul Declerck, Kevin Hollevoet
- Improved Potency and Safety of DNA-Encoded Antibody Therapeutics Through Plasmid Backbone and Expression Cassette Engineering(2021)
Authors: Giles Vermeire, Nick Geukens, Paul Declerck, Kevin Hollevoet
Pages: 1200 - 1209 - DNA-based delivery of anti-DR5 Nanobodies improves exposure and anti-tumor efficacy over protein-based administration(2021)
Authors: Giles Vermeire, Nick Geukens, Paul Declerck, Kevin Hollevoet
Pages: 828 - 838 - Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer(2020)
Authors: Liesl Jacobs, Nick Geukens, Paul Declerck, Kevin Hollevoet
- DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure(2020)
Authors: Liesl Jacobs, Nick Geukens, Paul Declerck, Kevin Hollevoet
Pages: 1068 - 1077 - Bridging the Clinical Gap for DNA-Based Antibody Therapy Through Translational Studies in Sheep(2019)
Authors: Kevin Hollevoet, Stéphanie De Vleeschauwer, Giles Vermeire, Nick Geukens, Paul Declerck
Pages: 1431 - 1443 - Intramuscular Electroporation of DNA-Based Monoclonal Antibodies in Sheep: A Translational Model for Clinical Antibody Gene Transfer(2018)
Authors: Kevin Hollevoet, Stephanie De Vleeschauwer, Elien De Smidt, Giles Vermeire, Nick Geukens, Paul Declerck
Pages: 178 - 179 - Prolonged expression and anti-tumor response of DNA-based anti-HER2 antibodies(2018)
Authors: Kevin Hollevoet, Nick Geukens, Paul Declerck
Pages: 13623 - 13636 - State of play and clinical prospects of antibody gene transfer(2017)
Authors: Kevin Hollevoet, Paul Declerck